Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients  Jiacong Luo, MD, MS, MPH, Donna E.

Slides:



Advertisements
Similar presentations
| 1| 1Peer Report: Dialysis Care & Outcomes in the U.S., 2014 | Incidence Peer Report: Dialysis Care & Outcomes in the U.S., 2014 Incidence.
Advertisements

Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.
2016 Annual Data Report, Vol 2, ESRD, Ch 5
2016 Annual Data Report, Vol 1, CKD, Ch 8
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
2016 Annual Data Report, Vol 2, ESRD, Ch 4
The Relationship Between Ultraviolet Light Exposure and Mortality in Dialysis Patients Am J Nephrol 2014;40: DOI: / Fig. 1. Association.
Thyroid Status and Death Risk in US Veterans With Chronic Kidney Disease  Connie M. Rhee, MD, MSc, Kamyar Kalantar-Zadeh, MD, MPH, PhD, Vanessa Ravel,
Chapter 2: Pharmacological cholesterol-lowering treatment in adults
Revisiting Interdialytic Weight Gain and Mortality Association With Serum Albumin Interactions: The Japanese Dialysis Outcomes and Practice Pattern Study 
Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.
Shoshana H. Ballew, PhD, Yan Chen, BS, Natalie R. Daya, MPH, Job G
Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,
In Reply to ‘The Importance of Icodextrin Use for Technique and Patient Survival in Peritoneal Dialysis’  Emily J. See, MBBS, David W. Johnson, PhD, Yeoungjee.
CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation  Walid Saliba, MD, MPH, Gad Rennert,
Volume 2: End-Stage Renal Disease
Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes  Eduardo Lacson, MD, MPH, Weiling Wang,
Surviving the First Year of Peritoneal Dialysis: Enduring Hard Times
ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target  Szu-Chun Hung, Der-Cherng Tarng  Kidney International 
Survival differences between peritoneal dialysis and hemodialysis among “large” ESRD patients in the United States  Austin G. Stack, Bhamidipati V.R.
Cardiovascular Disease and CKD: Core Curriculum 2010
Volume 64, Issue 3, Pages (September 2003)
IP155. Transplant Wait Listing Attenuates the Association Between Hemodialysis Access and Mortality  Courtenay Holscher, Sunjae Bae, Christine Haugen,
Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): Nutrition guidelines, indicators, and.
Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G
Syncope: Outcomes and Conditions Associated with Hospitalization
Anne M. Butler, PhD, Andrew F. Olshan, PhD, Abhijit V
Volume 145, Issue 1, Pages (January 2014)
Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval  Steven M. Brunelli, MD, MSCE,
Differences in Use of Peritoneal Dialysis and Survival Among East Asian, Indo Asian, and White ESRD Patients in Canada  Brenda R. Hemmelgarn, PhD, MD,
Volume 85, Issue 1, Pages (January 2014)
Molly E. Waring, PhD, Jane S
Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis  Connie M. Rhee, MD, MSc, Csaba P. Kovesdy,
Ioannis Koulouridis, MD, MS, Lori Lyn Price, MAS, Nicolaos E
The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle  Douglas S. Fuller, MS, Ronald L. Pisoni,
Vitality Measured as Self-reported Energy Level and Clinical Outcomes in Hemodialysis Patients: The Japanese Dialysis Outcomes and Practice Pattern Study.
Volume 76, Issue 10, Pages (November 2009)
Costs Five Years After Off-Pump or On-Pump Coronary Artery Bypass Surgery  Todd H. Wagner, PhD, Brack Hattler, MD, Faisal G. Bakaeen, MD, Joseph F. Collins,
David C. Mendelssohn, MD, FRCPC, Jay B. Wish, MD 
CKD and the Risk of Acute, Community-Acquired Infections Among Older People With Diabetes Mellitus: A Retrospective Cohort Study Using Electronic Health.
Volume 77, Issue 7, Pages (April 2010)
Stephen P. McDonald  Kidney International Supplements 
Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study  Wolfgang.
Jennifer E. Flythe, Stephen E. Kimmel, Steven M. Brunelli 
American Journal of Kidney Diseases
Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study  Eric D.
American Journal of Kidney Diseases
Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney.
Survival by time of day of hemodialysis: analysis of United States renal data system dialysis morbidity and mortality waves III/IV  Kevin C Abbott, MD,
Manish M. Tanna, MD, Edward F. Vonesh, PhD, Stephen M. Korbet, MD 
George L. Bakris, MD, John M. Burkart, MD, Eric D
Trends and Outcomes Associated With Serum Albumin Concentration Among Incident Dialysis Patients in the United States  George A. Kaysen, MD, PhD, Kirsten.
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
David A. Goodkin, MD, Eric W
Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD 
Volume 82, Issue 3, Pages (August 2012)
Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients  Finnian R. Mc Causland, Sushrut S.
K. Kalantar-Zadeh, J. D. Kopple, N. Kamranpour, A. M. Fogelman, M
The Use of Vaccines in Adult Patients With Renal Disease
American Journal of Kidney Diseases
Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley 
Pediatric in-center hemodialysis patients
Sushrut S. Waikar, MD, MPH, Gary C. Curhan, MD, ScD, Steven M
Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance1  William M.
Shoshana H. Ballew, PhD, Yan Chen, BS, Natalie R. Daya, MPH, Job G
Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes  Steven M. Brunelli, Ravi Thadhani,
Among three residual kidney function (RKF) indices, only residual urine volume (UV) indicated an independent prognostic value in patients with UV≥0.1 or.
Presentation transcript:

Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients  Jiacong Luo, MD, MS, MPH, Donna E. Jensen, PhD, Bradley J. Maroni, MD, Steven M. Brunelli, MD  American Journal of Kidney Diseases  Volume 68, Issue 5, Pages 763-771 (November 2016) DOI: 10.1053/j.ajkd.2016.05.031 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Study schematic. For the descriptive portion of the analysis (presented in Table 1), the point prevalence of erythropoiesis-stimulating agent (ESA) hyporesponsiveness according to 5 candidate definitions was considered at the beginning of 8 calendar quarters (indicated by Xs). For the associative analysis (presented in Tables 2 and 3 and Figs 2 and 3), patient demographic information was collected in the 90 days leading up to January 1, 2012 (through January 30 if required; black line). Patients were ascribed ESA hyporesponsiveness status if they met definition 4 at any time during quarter 1 2012 (solid grey line). Outcomes were assessed through December 31, 2013 (dashed grey line). American Journal of Kidney Diseases 2016 68, 763-771DOI: (10.1053/j.ajkd.2016.05.031) Copyright © 2016 The Authors Terms and Conditions

Figure 2 (A) Mean per-treatment erythropoiesis-stimulating agent (ESA) use, (B) monthly hemoglobin (Hb) levels, and (C) monthly intravenous (IV) iron use during follow-up. (A) Per-treatment ESA use mean values were adjusted for baseline differences in sex, age, race, cause of end-stage renal disease (ESRD), dialysis vintage, vascular access, cancer, parathyroid hormone level, albumin level, and Charlson Comorbidity Index score. The interaction between exposure and month was significant, P<0.001. Differences between ESA hyporesponsive (ESAhr) and non-ESAhr mean monthly per-treatment ESA use were significant in all months, P<0.001. (B) Monthly Hb mean values were adjusted for baseline differences in sex, age, race, cause of ESRD, dialysis vintage, vascular access, cancer, parathyroid hormone level, albumin level, and Charlson Comorbidity Index score. The interaction between exposure and month was significant, P<0.001. Differences between the ESAhr and non-ESAhr cohorts' Hb were significant in all months, P<0.001. (C) Monthly IV iron use mean values were adjusted for baseline differences in age, sex, race, Charlson Comorbidity Index score, serum albumin level, parathyroid hormone level, antibiotic use, peripheral vascular disease, hypertension, human immunodeficiency virus/AIDS, gastrointestinal bleed, coronary artery disease, chronic obstructive pulmonary disease, congestive heart failure, cancer, vascular access, dialysis vintage, and cause of ESRD. Differences between non-ESAhr and ESAhr IV iron use were significant in all months, P<0.001. American Journal of Kidney Diseases 2016 68, 763-771DOI: (10.1053/j.ajkd.2016.05.031) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Quarterly mortality incidence rate ratios (IRRs) during follow-up for patients with versus without erythropoiesis-stimulating agent hyporesponsiveness at baseline. Shown are the (A) unadjusted and (B) adjusted IRRs with 95% confidence intervals (CIs). Mortality rates, estimated using general estimating equation Poisson models with exchangeable correlation structure, were adjusted for differences at baseline in age, sex, cause of end-stage renal disease, dialysis vintage, vascular access, cancer, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease, coronary artery disease, gastrointestinal bleeding, human immunodeficiency virus/AIDS, peripheral vascular disease, intravenous (IV) antibiotic use, dry weight, serum ferritin level, saturated transferrin, parathyroid hormone level, albumin level, IV vitamin D use, and Charlson Comorbidity Index score. The interaction between exposure and quarter was significant, P<0.001. In determining all IRRs, ESA non-hyporesponsiveness rates served as the referent. American Journal of Kidney Diseases 2016 68, 763-771DOI: (10.1053/j.ajkd.2016.05.031) Copyright © 2016 The Authors Terms and Conditions